Hodgkin Lymphoma (HL)

C81WHO Vol. 11 (2024)

Haematolymphoid System

Prognosis

This section is being prepared by our editorial process.

🔬 Histological Types

📚 Latest Research

2026-09-07

Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma.

Febvey-Combes O, et al

A new study shows that an external control arm built from real-world clinical data can reliably replicate randomized trial outcomes in advanced-stage classical Hodgkin lymphoma, with a hazard ratio for progression-free survival of 0.98 (95% CI, 0.59–1.62) — nearly identical between arms. Using the French REALYSA prospective cohort, researchers constructed a 191-patient external control group by applying the eligibility criteria of the AHL2011 phase III RCT and propensity score weighting to balance baseline characteristics against 410 RCT patients. Overall response rates at the end of first-line treatment were also comparable between arms, and propensity score weighting outperformed matching in achieving covariate balance. These results support the use of real-world data-based external control studies as credible comparators in future clinical trials for advanced Hodgkin lymphoma, potentially reducing reliance on placebo-controlled arms.

Clinical pharmacology and therapeutics

Source →

2026-09-07

Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons.

Pearse WB, et al

A comprehensive review of lymphoid malignancies — encompassing more than 100 clinically distinct subtypes — underscores that these cancers achieve higher disease control rates than many solid tumors, with numerous cases remaining curable even when presenting with extensive disease involvement. Novel targeted therapies have meaningfully improved both disease control and cure rates across nearly all subtypes of lymphoid neoplasms, including lymphoma and myeloma. For surgical oncologists, the primary contribution to patient care is obtaining biopsies of sufficient quality to enable accurate diagnosis, though emergent surgical intervention remains necessary in select oncologic emergency scenarios.

Hematology/oncology clinics of North America

Source →

2026-09-04

How I Treat Pediatric Hematology-Oncology Patients from Families Identifying as Jehovah's Witnesses.

Weaver MS, et al

A clinical guidance article published in Blood establishes a practical, ethics-informed framework for managing pediatric hematology-oncology patients from Jehovah's Witness families who may refuse blood transfusions, underscoring that family preferences are heterogeneous and shaped by individual conscience, cultural context, and personal interpretation of religious doctrine rather than by a single uniform position. Through three illustrative cases — an adolescent with relapsed Hodgkin lymphoma being considered for autologous hematopoietic cell transplantation, an infant with severe aplastic anemia involving intrafamilial disagreement and legal intervention, and a child requiring chronic transfusions — the authors detail evidence-based transfusion-averse strategies including anemia mitigation, bleeding prophylaxis, and blood conservation techniques. The article further addresses ethical thresholds for overriding parental refusal, the appropriate use of preemptive court orders, and communication practices aimed at preserving trust and minimizing moral distress, concluding that individualized, interdisciplinary care can honor religious beliefs while achieving safe, patient-centered outcomes.

Blood

Source →